Cantitate/Preț
Produs

Bortezomib in the Treatment of Multiple Myeloma: Milestones in Drug Therapy

Editat de Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson
en Limba Engleză Hardback – 11 noi 2010
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Citește tot Restrânge

Din seria Milestones in Drug Therapy

Preț: 67883 lei

Preț vechi: 71456 lei
-5% Nou

Puncte Express: 1018

Preț estimativ în valută:
12994 13971$ 10832£

Carte tipărită la comandă

Livrare economică 19 decembrie 24 - 02 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783764389475
ISBN-10: 3764389478
Pagini: 250
Ilustrații: VIII, 180 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.44 kg
Ediția:2011
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy

Locul publicării:Basel, Switzerland

Public țintă

Research

Cuprins

.

Textul de pe ultima copertă

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

Caracteristici

Contemporary monograph on Bortezomib and the proteasome discovery from the lab to the clinic A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology Depicts the biochemical background of the drug action